EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice

Anne R Schlösser iD, Madena Shareef, Jill Olydam iD, Tamar E C Nijsten iD, Dirk Jan Hijnen iD

Clinical and Experimental Dermatology · 2023

DOI: 10.1093/ced/llad038 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Anne R Schlösser und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence about tralokinumab treatment for moderate-to-severe atopic dermatitis (AD) in daily practice is limited.

Aim

To report the first evidence, to our knowledge, from daily practice of treatment with tralokinumab in patients with AD.

Methods

In this observational prospective study, patients with AD who received tralokinumab treatment in the context of routine care at the Erasmus Medical Centre were included between November 2021 and February 2022. This included 28 patients who had previously been treated with dupilumab, and 14 patients who had been treated with a Janus kinase inhibitor (JAKi). The Investigator’s Global Assessment (IGA; 0–4) and the numeric rating scale peak pruritus during the past 7 days (NRS itch 7d: 0–10), adverse events and reasons for discontinuation were analysed. A good clinical response was defined as any decrease in IGA and NRS itch 7d and if a patient was satisfied with the treatment and wished to continue with therapy.

Results

In total, 37 patients were treated with tralokinumab. Twenty-two (59%) patients showed a good response to tralokinumab treatment. Fifteen (41%) patients discontinued treatment because of inadequate AD control or adverse events. Treatment-related adverse events were mild in most patients. Half of the patients where treatment with dupilumab had failed had a good clinical response to tralokinumab.

Conclusions

Tralokinumab was found to be effective in most patients in this cohort with difficult-to-treat, severe AD from daily practice. Interestingly, tralokinumab was also found to be effective in 50% of patients who had previously experienced insufficient response or adverse events with dupilumab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansProspective StudiesSeverity of Illness IndexPruritusDouble-Blind MethodImmunoglobulin ATreatment OutcomeAntibodies, Monoclonal

Substanzen

Immunoglobulin AtralokinumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

ORCID-Profile: Anne R Schlösser, Jill Olydam, Tamar E C Nijsten, Dirk Jan Hijnen

Zitieren

APA

Schlösser, A. R., Shareef, M., Olydam, J., Nijsten, T. E. C., & Hijnen, D. J. (2023). Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad038

Vancouver

Schlösser AR, Shareef M, Olydam J, Nijsten TEC, Hijnen DJ. Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad038

BibTeX
@article{Schlsser2023,
  author = {Schlösser, Anne R and Shareef, Madena and Olydam, Jill and Nijsten, Tamar E C and Hijnen, Dirk Jan},
  title = {Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  doi = {10.1093/ced/llad038}
}
Kostenlos starten →